These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 6419680)

  • 1. Studies on amelanotic melanoma with the fluorescence method (Falck and Hillarp) and biochemical analysis of 5-S-cysteinyldopa in the tissues.
    Morishima T; Tatsumi F; Fukada E; Watanabe M; Nagashima N; Hanawa S
    Arch Dermatol Res; 1983; 275(5):329-33. PubMed ID: 6419680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Diagnosis of amelanotic malignant melanoma by means of the fluorescence method (Falck & Hillarp) and determination of 5-S-cysteinyldopa in the lesions].
    Morishima T; Fukada E; Nagashima N
    Nihon Hifuka Gakkai Zasshi; 1983 Jan; 93(1):51-4. PubMed ID: 6408288
    [No Abstract]   [Full Text] [Related]  

  • 3. [Biochemical diagnoses of malignant melanomas with determinations of 5-S-cysteinyldopa in lesions].
    Sameshima T; Morishima T
    Nihon Hifuka Gakkai Zasshi; 1989 May; 99(6):665-72. PubMed ID: 2511358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Free and bound 5-S-cysteinyldopa and dopa in human malignant melanomas.
    Agrup G; Hansson C; Rorsman H; Rosengren AM; Rosengren E
    Acta Derm Venereol; 1978; 58(3):270-2. PubMed ID: 78645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On the occurrence of cysteinyldopa and dopa in melanocytes and benign nevi cells.
    Falck B; Jacobsson S; Lindvall O; Nietsche UB
    Scand J Plast Reconstr Surg; 1976; 10(3):185-8. PubMed ID: 1053447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tyrosinase and gamma-glutamyl transpeptidase in 5-s-cysteinyldopa genesis within melanotic and amelanotic melanomas.
    Mojamdar M; Ichihashi M; Mishima Y
    J Dermatol; 1982 Feb; 9(1):73-7. PubMed ID: 6124565
    [No Abstract]   [Full Text] [Related]  

  • 7. [Definitive diagnosis of early malignant melanoma lesions by the quantitative analysis of 5-S-cysteinyldopa in the tissue and touch fluorescence method].
    Kanematsu S; Morishima T
    Nihon Hifuka Gakkai Zasshi; 1989 Jun; 99(7):783-91. PubMed ID: 2511360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5 years' experience of 5-S-cysteinyldopa in melanoma diagnosis.
    Agrup G; Agrup P; Andersson T; Hafström L; Hansson C; Jacobsson S; Jönsson PE; Rorsman H; Rosengren AM; Rosengren E
    Acta Derm Venereol; 1979; 59(5):381-8. PubMed ID: 93360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection and quantitation of 5-S-cysteinyldopa in melanotic and amelanotic melanoma in comparison with nonpigment cell tumors and it's urinary excretion.
    Mojamdar M; Ichihashi M; Mishima Y
    J Dermatol; 1979 Dec; 6(6):379-82. PubMed ID: 120380
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of DOPA-loading on glutathione-dependent 5-S-cysteinyldopa genesis in melanoma cells in vitro.
    Mojamdar M; Ichihashi M; Mishima Y
    J Invest Dermatol; 1982 Mar; 78(3):224-6. PubMed ID: 6799583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cysteinyldopa isomers and dopa in lesions and urine of Japanese patients with malignant melanoma.
    Morishima T; Tatsumi F; Fukada E; Saito M; Fujita M; Nagashima N; Hanawa S
    Arch Dermatol Res; 1983; 275(2):76-9. PubMed ID: 6409012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pigmented spindle cell nevus and pigmented Spitz nevus--clinical and histopathological study on pigmented Spitz nevus, and its differentiation from early melanoma by fluorescence method and measurement of 5-S-CD level in the lesion].
    Takeuchi M; Morishima T
    Nihon Hifuka Gakkai Zasshi; 1990 Oct; 100(11):1153-65. PubMed ID: 2273578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary free and conjugated 5-S-cysteinyldopa in normal subjects and in patients with melanoma.
    Graef V; Paul E
    Br J Dermatol; 1982 Jan; 106(1):53-7. PubMed ID: 6800394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quick diagnosis of malignant melanoma with the touch-fluorescence method during operation.
    Morishima T; Nagashima N; Hanawa S; Fukada E; Kanematsu S; Shibata A
    Cancer; 1986 May; 57(10):2037-41. PubMed ID: 3955511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma 5-S-cysteinyldopa differentiates patients with primary and metastatic melanoma from patients with dysplastic nevus syndrome and normal subjects.
    Peterson LL; Woodward WR; Fletcher WS; Palmquist M; Tucker MA; Ilias A
    J Am Acad Dermatol; 1988 Sep; 19(3):509-15. PubMed ID: 3139723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-S-cysteinyldopa in the urine of melanoma patients.
    Agrup G; Agrup P; Andersson T; Falck B; Hansson JA; Jacobsson S; Rorsman H; Rosengren E; Rosengren AM
    Acta Derm Venereol; 1977; 57(2):113-6. PubMed ID: 71802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pagetoid malignant melanoma and lentigo maligna melanoma of toe. A study with the fluorescence method (Falck and Hillarp).
    Morishima T; Ishikawa T; Endo M; Tsujiguchi Y
    Arch Dermatol Res; 1978 Aug; 262(3):275-83. PubMed ID: 718255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopaquinone addition products in cultured human melanoma cells.
    Carstam R; Hansson C; Lindbladh C; Rorsman H; Rosengren E
    Acta Derm Venereol; 1987; 67(2):100-5. PubMed ID: 2438872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. gamma-Glutamyl transpeptidase, tyrosinase, and 5-S-cysteinyldopa production in melanoma cells.
    Mojamdar M; Ichihashi M; Mishima Y
    J Invest Dermatol; 1983 Aug; 81(2):119-21. PubMed ID: 6135733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma 5-S-cysteinyldopa correlates with tumor size in melanoma-bearing mice.
    Hu F; Woodward WR; Peterson LL
    J Invest Dermatol; 1988 Feb; 90(2):149-51. PubMed ID: 3123557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.